Filtered by Category: Lead Counsel

Pomerantz Appointed Lead Counsel in loanDepot Securities Litigation

On May 2, 2022, U.S. District Judge Josephine L. Staton of the Central District of California appointed Pomerantz LLP as Lead Counsel on behalf of Arthur Gary LaFrano, the Lead Plaintiff, and the class, in Eljon Lako v. Loandepot, Inc. et al, 8:21-cv-01449-JLS-JDE (C.D. Cal.). This securities action alleges that loanDepot, Inc. ("loanDepot" or the "Company") failed to disclose declines in its loan operation business that negatively impacted its revenue and growth. loanDepot is an independent retail mortgage lender that provides residential loans, refinance loans, and personal loan products nationwide. Allegations against loanDepot include that…

Read More

Pomerantz Appointed Co-Lead Counsel in NRx Pharmaceuticals Securities Litigation

On April 6, 2022, U.S. District Judge Maryellen Noreika of the District of Delaware appointed Pomerantz LLP as Co-Lead Counsel on behalf of the Co-Lead Plaintiff, and the class, in NRx Pharmaceuticals, Inc., 1:22-cv-00066-MN (D. Del.). This securities action alleges that NRx Pharmaceuticals, Inc. misrepresented the efficacy and regulatory prospects of ZYESAMI (also known as aviptadil), its investigational pre-commercial drug for the treatment COVID-19 related respiratory failure. NRx is a clinical-stage pharmaceutical company that develops various therapeutics for the treatment of central nervous system disorders and the treatment and prevention…

Read More

Pomerantz Appointed Lead Counsel in Ginkgo Bioworks Securities Litigation

On March 25, 2022, U.S. District Judge Yvonne Gonzalez Rogers of the Northern District of California (Oakland Division) appointed Pomerantz LLP as Lead Counsel on behalf of Sharon Bernstein, the Lead Plaintiff, and the class, in Stuart v. Ginkgo Bioworks Holdings, Inc., 4:21-cv-08943-YGR (N.D.Ca.). This securities action alleges that Ginkgo Bioworks Holdings, Inc. misrepresented and misclassified its sources of revenue in order to conceal its dependence on undisclosed related parties. Ginkgo is a biotech company that operates a platform for cell programming, designed to enable biological production of products as diverse as novel…

Read More

Pomerantz Appointed Lead Counsel in Höegh LNG Securities Litigation

On March 11, 2022, U.S. District Judge Kevin McNulty of the District of New Jersey appointed Pomerantz LLP as Lead Counsel on behalf of Yen-Hsun Huang and Scott Miller, the Co-Lead Plaintiffs, and the class, in In re Höegh LNG Partners LP Sec. Lig., 21-cv-19374 (D.N.J.). This securities action alleges that Höegh LNG Partners LP misrepresented and failed to disclose that the Partnership was experiencing low demand and difficulties related to the financing of its floating storage and regasification units . The Partnership provides floating liquefied natural gas services, including LNG transportation services, LNG regasification, terminal solutions, and other management services.

Read More

Pomerantz Appointed Co-Lead Counsel in Camber Energy Securities Litigation

On March 14, 2022, U.S. District Judge Charles Eskridge of the Southern District of Texas (Houston Division) appointed Pomerantz LLP as Co-Lead Counsel on behalf of Robert Laurent and Ajmal Hussain, Co-Lead Plaintiffs, and the class in Coggins v. Camber Energy, Inc., 21-cv-3574 (S.D. Tex.). This securities action alleges that Camber Energy, Inc. (“Camber” or the “Company”) overstated the financial and business prospects related to its acquisition of Viking Energy Group, Inc. (“Viking”) and downplayed problems arising from that acquisition. Camber is an energy company that develops and produces crude oil, natural gas, and natural gas liquids.

Read More

Pomerantz Appointed Lead Counsel in TMC Securities Litigation

On March 7, 2022, U.S. Magistrate Judge Sanket J. Bulsara of the Eastern District of New York appointed Pomerantz LLP as Lead Counsel on behalf of Co-Lead Plaintiffs, Point12 Diversified Fund, LP and Kyle Autry, and the class, in Carper v. TMC Metals Company Inc., 21-cv-5991 (E.D.N.Y.). This securities action concerns allegations that TMC the Metals Company, Inc. (“TMC” or the “Company”) overpaid for licenses, inflated expenses and affiliated with bad actors. TMC is a Canadian deep-sea minerals exploration company focused on the collection, processing, and refining of battery-grade metals from the seafloor. The Company’s purported mission is to supply metals…

Read More

Pomerantz Appointed Lead Counsel in Silverback Therapeutics Securities Litigation

On February 23, 2022, U.S. Magistrate Judge Theresa L. Fricke of the Western District of Washington (Tacoma) appointed Pomerantz LLP as Lead Counsel on behalf of Lead Plaintiff, Benjamin Dresner, and the class, in Dresner v. Silverback Therapeutics, Inc., 21-cv-1499 (W.D. Wash.). Silverback Therapeutics, Inc. (“Silverback” or the “Company”) is a biopharmaceutical company that develops tissue-targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The litigation concerns allegations that Silverback’s Offering Documents for its December 2020 IPO misrepresented the efficacy and commercial…

Read More

Pomerantz Appointed Lead Counsel in Lightspeed Commerce Securities Litigation

On February 22, 2022, U.S. District Judge Brian M. Cogan of the Eastern District of New York appointed Pomerantz LLP as Lead Counsel on behalf of Debrob Investments Limited, the Lead Plaintiff in Lightspeed Commerce Inc., 21-cv-6365 (E.D.N.Y.), a securities action brought on behalf of a class of defrauded investors concerning allegations that Lightspeed Commerce Inc. overstated the strength of its business while concealing the Company’s declining organic growth and the deterioration of its business. Lightspeed is a commerce software provider that offers a cloud-based platform to small and midsize businesses that enables…

Read More

Pomerantz Appointed Co-Lead Counsel in Canoo Securities Litigation

On February 18, 2022, U.S. District Judge Fernando M. Olguin of the Central District of California appointed Pomerantz LLP as Co-Lead Counsel on behalf of Vladi Shaulov, the Lead Plaintiff in Blake v. Canoo Inc., 21-cv-2873 (C.D. Cal.), a securities action brought on behalf of a class of defrauded investors concerning allegations that Canoo Inc. misrepresented the viability of its engineering service and its ability to produce meaningful revenue. Canoo designs consumer and commercial electric vehicles based on a multi-purpose modular platform, with the intention of manufacturing cars, minivans and delivery vehicles. Allegations against Canoo include…

Read More

Pomerantz Appointed Lead Counsel in Zhangmen Education Securities Litigation

On February 11, 2022, U.S. District Judge J. Paul Oetken of the Southern District of New York appointed Pomerantz LLP as Lead Counsel on behalf of Yanhong Chen, the Lead Plaintiff in Bannerjee v. Zhangmen Education Inc., 21-cv-9634 (S.D.N.Y.), a securities action brought on behalf of a class of defrauded investors concerning allegations that Zhangmen Education Inc.’s Offering Documents for its June 2017 IPO failed to disclose known risks of impending new regulatory reforms in China that were reasonably likely to have a material adverse effect on the Company's business and financial performance. Zhangmen is an online education platform…

Read More

Pomerantz Appointed Co-Lead Counsel in Novavax Securities Litigation

On January 26, 2022, U.S. District Judge Theodore D. Chuang of the District of Maryland appointed Pomerantz LLP as Co-Lead Counsel on behalf of Nuggehalli Balmukund Nandkumar and Jeffrey A. Gabbert, Co-Lead Plaintiffs with another Co-Lead Plaintiff in Sinnathurai v. Novavax, Inc., 21-cv-2910 (D. Md.), a securities action brought on behalf of a class of defrauded investors concerning allegations that Novavax, Inc. failed to disclose manufacturing issues with its lead vaccine candidate for COVID-19. Novavax is a biopharmaceutical company that develops vaccines to prevent serious infectious diseases, including NVX-CoV2373, its coronavirus vaccine…

Read More

Pomerantz Appointed Lead Counsel in Nano-X Imaging Securities Litigation

On January 25, 2022, U.S. Magistrate Judge Peggy Kuo of the Eastern District of New York appointed Pomerantz LLP as Lead Counsel on behalf of Davian Holdings Limited, the Lead Plaintiff in McLaughlin v. Nano-X Imaging Ltd., 21-cv-5517 (E.D.N.Y.), a securities action brought on behalf of a class of defrauded investors concerning allegations that Nano-X Imaging Ltd. misrepresented the regulatory and commercial prospects of its Nanox.ARC digital x-ray medical imaging system. Nano-X develops medical imaging technology, including digital x-ray systems, cloud-based image analysis and online diagnosis solutions, and billing services systems.

Read More

Pomerantz Appointed Lead Counsel in Neptune Wellness Solutions Securities Litigation

On January 4, 2022, U.S. Magistrate Judge Arlene R. Lindsay of the Eastern District of New York appointed Pomerantz LLP as Lead Counsel on behalf of Kenneth Rickert, the Lead Plaintiff in Gong v. Neptune Wellness Solutions Inc., 21-cv-1386 (E.D.N.Y.), a securities action brought on behalf of a class of defrauded investors concerning allegations that Neptune Wellness Solutions, Inc. failed to disclose the true cost and financial strain of integrating the assets and operations that it had acquired from SugarLeaf Labs, LLC and Forest Remedies LLC (collectively, “SugarLeaf”), two commercial hemp companies. Neptune operates as…

Read More

Pomerantz Appointed Lead Counsel in Emergent Biosolutions Securities Litigation

On December 23, 2021, U.S. District Judge Paul W. Grimm, of the District of Maryland, appointed Pomerantz LLP as Lead Counsel on behalf of Nova Scotia Health Employees’ Pension Plan and the City of Fort Lauderdale Police & Firefighters’ Retirement System, the Lead Plaintiffs in In re Emergent Biosolutions Inc., 21-cv-995 (D. Md.), a securities action brought on behalf of a class of defrauded investors concerning allegations that Emergent BioSolutions Inc. had a manufacturing and quality control issues with the product of vaccines which resulted in the need to destroy contaminated vaccines and FDA citations. Emergent is a…

Read More

Pomerantz Appointed Lead Counsel in AcelRx Pharmaceuticals Securities Litigation

On December 16, 2021, U.S. District Judge Beth Labson Freeman, of the Northern District of California – San Jose Division, appointed Pomerantz LLP as Lead Counsel on behalf of Aaron Sneed and Yaacov Musry, the Lead Plaintiffs in Sneed Jr. v. AcelRx Pharmaceuticals, Inc. et al, 21-cv-4353 (N.D. Cal.), a securities action brought on behalf of a class of defrauded investors concerning allegations that AcelRx Pharmaceuticals, Inc. made false or misleading claims and representations in marketing materials about the risks and efficacy of DSUVIA, its lead product candidate for the treatment of moderate-to-severe…

Read More

Pomerantz Appointed Lead Counsel in Generac Holdings Securities Litigation

On December 15, 2021, U.S. District Judge Lynn Adelman of the Eastern District of Wisconsin appointed Pomerantz LLP as Lead Counsel on behalf of Carey Don Procter, the Lead Plaintiffs in In re Generac Holdings Inc. Sec. Litig., 21-cv-1342 (E.D. Wis.), a securities action brought on behalf of a class of defrauded investors concerning allegations that Generac Holdings Inc. had made false and misleading statements regarding product safety, product recalls, and the impact that these issues would have on revenue. Generac designs and manufactures a wide range of energy technology solutions, which provides…

Read More

Pomerantz Appointed Co-Lead Counsel in Nikola Corporation Securities Litigation

On November 18, 2021, U.S. District Judge Steven P. Logan of the District of Arizona appointed Pomerantz LLP as Co-Lead Counsel on behalf of Vincent Chau, Stanley Karcynski, and George Mersho, the Lead Plaintiffs in Borteanu v. Nikola Corporation, 20-cv-1797 (D. Ariz.), a securities action brought on behalf of a class of defrauded investors concerning allegations that Nikola Corporation had made false and misleading statements regarding its business operations, financial growth prospects and the viability of its fuel cell technology. Nikola manufactures commercial electric vehicles and energy solutions, providing battery…

Read More

Pomerantz Appointed Lead Counsel in ATI Physical Therapy Securities Litigation

On November 18, 2021, U.S. District Judge Edmond E. Chang of the Northern District of Illinois appointed Pomerantz LLP as Lead Counsel on behalf of Phoenix Insurance Company Ltd. and The Phoenix Pension & Provident Funds, Lead Plaintiffs in Burbige v. ATI Physical Therapy, Inc., 21-cv-4349 (N.D. Ill.), a securities action brought on behalf of a class of defrauded investors concerning allegations that ATI Physical Therapy, Inc. had made false and misleading statements regarding its business operations and financial performance. ATI is an outpatient physical therapy company.

Read More

Pomerantz Appointed Lead Counsel in Provention Bio Securities Litigation

On November 17, 2021, U.S. District Judge Michael A. Shipp of the District of New Jersey appointed Pomerantz LLP as Lead Counsel on behalf of George L. Jordan, Jr., Lead Plaintiff in Paxton v. Provention Bio, Inc., 21-cv-11613 (D.N.J.), a securities action brought on behalf of a class of defrauded investors concerning allegations that Provention Bio, Inc. had made false and misleading statements regarding the sufficiency of testing data and approval prospects for its lead product candidate for the treatment of type one diabetes Provention is a clinical stage biopharmaceutical company that develops and…

Read More

Pomerantz Appointed Lead Counsel in Raytheon Securities Litigation

On November 17, 2021, U.S. District Judge John C. Hinderaker of the District of Arizona appointed Pomerantz LLP as Lead Counsel on behalf of the State Teachers Retirement System of Ohio, Lead Plaintiff in Bajjuri v. Raytheon Technologies Corporation, 20-cv-00468 (D. Ariz.), a securities action brought on behalf of a class of defrauded investors concerning allegations that Raytheon Technologies Corporation had made false and misleading statements regarding the effectiveness of Raytheon’s internal controls over financial reporting and disclosure controls and procedures, as well as a number of relevant financial metrics. Raytheon purports to be…

Read More